☆ 4.6 Editorial Material

The German 2011 epidemic of Shiga toxin-producing E. Coli-the nephrological view

NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)

Journal

NEPHROLOGY DIALYSIS TRANSPLANTATION

Volume 26, Issue 9, Pages 2723-U1500

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/ndt/gfr462

Keywords

acute kidney injury; crisis management; German Society of Nephrology; hemolytic uremic syndrome; therapeutic plasma exchange

Categories

Transplantation Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Urology & Nephrology

Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial

Arnaud Garnier, Karine Brochard, Theresa Kwon, Anne-Laure Sellier-Leclerc, Annie Lahoche, Emma Allain Launay, Francois Nobili, Mathilde Caillez, Sophie Taque, Jerome Harambat, Guylhene Michel-Bourdat, Vincent Guigonis, Marc Fila, Sylvie Cloarec, Djeddi Djamal-Dine, Loic de Parscaux, Lise Allard, Remi Salomon, Tim Ulinski, Veronique Fremeaux-Bacchi, Christophe Morin, Pascale Olivier-Abbal, Helene Colineaux, Francoise Auriol, Catherine Arnaud, Isabelle Kieffer, Clara Brusq

Summary: This study examined the use of eculizumab in children with STEC-HUS and found that it did not improve renal outcomes during the acute phase of the disease, but may reduce long-term kidney sequelae.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Add to Collection

Article Urology & Nephrology

Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial

Arnaud Garnier, Karine Brochard, Theresa Kwon, Anne-Laure Sellier-Leclerc, Annie Lahoche, Emma Allain Launay, Francois Nobili, Mathilde Caillez, Sophie Taque, Jerome Harambat, Guylhene Michel-Bourdat, Vincent Guigonis, Marc Fila, Sylvie Cloarec, Djeddi Djamal-Dine, Loic de Parscaux, Lise Allard, Remi Salomon, Tim Ulinski, Veronique Fremeaux-Bacchi, Christophe Morin, Pascale Olivier-Abbal, Helene Colineaux, Francoise Auriol, Catherine Arnaud, Isabelle Kieffer, Clara Brusq

Summary: In pediatric patients with STEC-HUS, treatment with eculizumab does not appear to improve renal outcome during the acute phase of the disease but may reduce long-term kidney sequelae.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Therapeutic plasma exchange in paediatric nephrology in Ireland

Dermot M. Wildes, Conor Devlin, Caoimhe Suzanne Costigan, Tara Raftery, Conor Hensey, Mary Waldron, Niamh Dolan, Michael Riordan, Clodagh Sweeney, Maria Stack, Melanie Cotter, Bryan Lynch, Kathleen Mary Gorman, Atif Awan

Summary: A large retrospective review of paediatric patients undergoing TPE for renal indications in Ireland found that most patients experienced minor complications during treatment, with asymptomatic hypocalcaemia being the most common.

IRISH JOURNAL OF MEDICAL SCIENCE (2023)

Add to Collection

Article Pediatrics

Therapeutic Plasma Exchange in Children - Experience From a Tertiary Care Center

Rufaida Mazahir, Kanav Anand, P. K. Pruthi

Summary: The study demonstrates that therapeutic plasma exchange can be safely and effectively used in pediatric patients for both renal and non-renal diseases. The main indications include renal and neurological illnesses, with atypical hemolytic uremic syndrome (aHUS) being the most common indication.

INDIAN PEDIATRICS (2021)

Add to Collection

Review Urology & Nephrology

Klotho in Clinical Nephrology Diagnostic and Therapeutic Implications

Javier A. Neyra, Ming Chang Hu, Orson W. Moe

Summary: Klotho, a membrane protein that serves as a coreceptor for FGF23, is essential for maintaining organ function and preventing multiorgan failure. Systemic Klotho deficiency is commonly associated with kidney diseases. While Klotho shows promise in clinical applications, further research and large prospective human studies are needed to fully understand its diagnostic and therapeutic potential.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Thomas Barbour, Marie Scully, Gema Ariceta, Spero Cataland, Katherine Garlo, Nils Heyne, Yosu Luque, Jan Menne, Yoshitaka Miyakawa, Sung-Soo Yoon, David Kavanagh

Summary: Ravulizumab demonstrates long-term efficacy and safety in adults with aHUS, providing additional clinical benefits beyond 6 months of treatment, with most adverse events occurring early during the initial evaluation period and decreasing over time.

KIDNEY INTERNATIONAL REPORTS (2021)

Add to Collection

Article Health Care Sciences & Services

Compound Haplotype Variants in CFH and CD46 Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)-A Series of Cases from a Single Family

Agnieszka Furmanczyk-Zawiska, Anna Kubiak-Dydo, Ewelina Uzarowska-Gaska, Marta Kotlarek-Lysakowska, Katarzyna Salata, Monika Kolanowska, Michal Swierniak, Pawel Gaj, Beata Leszczynska, Maria Daniel, Krystian Jazdzewski, Magdalena Durlik, Anna Wojcicka

Summary: Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic defects, with variable clinical outcomes, including renal failure. This study presents cases of five family members affected by aHUS, demonstrating the highly variable penetrance of the disease.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Article Urology & Nephrology

Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation

Benjamin Thoreau, Florent von Tokarski, Adeline Bauvois, Guillaume Bayer, Christelle Barbet, Sylvie Cloarec, Elodie Merieau, Sebastien Lachot, Denis Garot, Louis Bernard, Emmanuel Gyan, Franck Perrotin, Claire Pouplard, Francois Maillot, Philippe Gatault, Benedicte Sautenet, Emmanuel Rusch, Veronique Fremeaux-Bacchi, Cecile Vigneau, Fadi Fakhouri, Jean-Michel Halimi

Summary: The study retrospectively examined 530 consecutive patients with thrombotic microangiopathies and found that infections unrelated to STEC accounted for 27% of cases, while STEC-unrelated infections without thrombotic microangiopathies accounted for 66% of cases. These infections were associated with older age, male gender, altered consciousness, lower blood pressure, lower hemoglobin and platelet count, and acute kidney injury. They were more common in patients with multiple pathogens and were independent risk factors for in-hospital death, major cardiovascular events, and acute dialysis. Enterobacteria, S. aureus, Epstein-Barr virus, and cytomegalovirus were the most common pathogens associated with these infections.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

Reimagining Nephrology Fellowship Education to Meet the Future Needs of Nephrology A Report of the American Society of Nephrology Task Force on the Future of Nephrology

Mark E. Rosenberg, Sharon Anderson, Samira S. Farouk, Keisha L. Gibson, Robert S. Hoover, Benjamin D. Humphreys, Janis M. Orlowski, Suneel M. Udani, Joshua S. Waitzman, Melissa West, Tod Ibrahim

Summary: The American Society of Nephrology (ASN) Task Force on the Future of Nephrology was established to address training requirements and improve the quality of care in nephrology. The task force developed 10 recommendations to promote equitable care, highlight the value of nephrology, and enhance nephrology education. This report reviews the process, rationale, and details of these recommendations.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Add to Collection

Review Immunology

The role of the complement system in kidney glomerular capillary thrombosis

Yoko Yoshida, Hiroshi Nishi

Summary: This article introduces the importance of the complement system in innate immunity and its interaction with platelets, neutrophils, endothelial cells, and other components. Complement dysregulation may lead to vascular injury and thrombosis in the kidneys, and further investigation is needed to develop specific therapeutic approaches.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Urology & Nephrology

Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease

Adi Nitzan-Luques, Mordechai Slae, Diaa Zugayar, Bradley P. Dixon, Karen Meir, Oded Volovelsky

Summary: Neonatal thrombotic microangiopathy (TMA) is a rare and severe disease characterized by a triad of symptoms in neonates. This case study describes a unique presentation of neonatal TMA associated with Hirschsprung disease, highlighting the importance of considering a TMA diagnosis in atypical neonatal presentations. Treatment included anti-C5 monoclonal antibody therapy and intestinal surgery.

JOURNAL OF NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findingss and outcomes of a case series in adults and children treated with eculizumab

Lilian Monteiro Pereira Palma, Renato George Eick, Gustavo Coelho Dantas, Michele Karen dos Santos Tino, Maria Izabel de Holanda

Summary: This study is the largest case series of aHUS in Brazil involving a wide range of patients for which eculizumab was the main treatment. Although eculizumab was started later than advised in the guidelines, most patients were able to stop dialysis at variable intervals. Discontinuation of eculizumab was associated with a 30% relapse of aHUS.

CLINICAL KIDNEY JOURNAL (2021)

Add to Collection

Article Urology & Nephrology

Therapeutic Plasma Exchange in the Critically Ill Patient: Technology and Indications

Amber P. Sanchez, Rasheed A. Balogun

Summary: Therapeutic plasma exchange (TPE) is commonly used for extracorporeal therapy in a variety of clinical indications, especially in cases requiring intensive care. Traditional TPE utilizes centrifugal forces or membrane filtration to remove disease mediators from plasma. This article reviews the basic principles, technological aspects, and clinical scenarios of TPE in intensive care, following guidelines from the American Society for Apheresis.

ADVANCES IN CHRONIC KIDNEY DISEASE (2021)

Add to Collection

Article Urology & Nephrology

Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation

Caroline Duineveld, Romy N. Bouwmeester, Kioa L. Wijnsma, F. J. Bemelman, J. W. van der Heijden, S. P. Berger, L. P. W. J. van den Heuvel, Nicole C. A. J. van de Kar, Jack F. M. Wetzels

Summary: Kidney transplantation in aHUS patients in the Netherlands is performed without eculizumab prophylaxis, and eculizumab therapy is given in case of posttransplant aHUS recurrence. The study found a recurrence rate of 23% without eculizumab prophylaxis, and eculizumab treatment effectively improved or stabilized kidney function in most patients.

KIDNEY INTERNATIONAL REPORTS (2023)

Add to Collection

Article Urology & Nephrology

Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored Eculizumab

Gianluigi Ardissino, Donata Cresseri, Francesca Tel, Antenore Giussani, Stefania Salardi, Martina Sgarbanti, Bice Strumbo, Sara Testa, Valentina Capone, Samantha Griffini, Elena Grovetti, Massimo Cugno, Mirco Belingheri, Chiara Tamburello, Evangeline Millicent Rodrigues, Michela Perrone, Massimo Cardillo, Grazia Corti, Dario Consonni, Lucrezia Furian, Silvana Tedeschi, Piergiorgio Messa, Claudio Beretta

Summary: This study presents experience with KTx in aHUS patients, showing that prophylactic use of Eculizumab can significantly reduce relapse rates. Tailored timing of Eculizumab doses based on classical complement pathway activity for each patient has also shown positive results.

JOURNAL OF NEPHROLOGY (2021)

Add to Collection

Letter Pharmacology & Pharmacy

Effectiveness of CytoSorb in cases of acute amitriptyline intoxication is not proven

Jan T. Kielstein, Julius J. Schmidt, Marc Ghannoum

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

Add to Collection

Review Urology & Nephrology

Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup

Josee Bouchard, Christopher Yates, Diane P. Calello, Sophie Gosselin, Darren M. Roberts, Valery Lavergne, Robert S. Hoffman, Marlies Ostermann, Ai Peng, Marc Ghannoum

Summary: Toxicity from gabapentin and pregabalin overdose often requires supportive treatment with the use of extracorporeal treatments (ECTRs) being controversial. The EXTRIP workgroup reviewed literature and concluded that ECTR may be beneficial for patients with decreased kidney function, but there is limited clinical data to support this recommendation. In cases of gabapentinoid poisoning, the workgroup suggests against routine use of ECTR in patients with normal kidney function. However, if there is decreased kidney function and coma requiring mechanical ventilation, the addition of ECTR to standard care may be considered.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

Add to Collection

Editorial Material Critical Care Medicine

Is This the Beginning of the End of Cytokine Adsorption?

Jan T. Kielstein, Alexander Zarbock

CRITICAL CARE MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries

M. Linschoten, A. Uijl, A. Schut, C. E. M. Jakob, L. R. Romao, R. M. Bell, E. McFarlane, M. Stecher, A. G. M. Zondag, E. P. A. van Iperen, J. F. Hermans-van Ast, N. C. Lea, J. Schaap, L. S. Jewbali, P. C. Smits, R. S. Patel, A. Aujayeb, M. van Smeden, H. J. Siebelink, S. Williams, L. Pilgram, R. G. Tieleman, B. Williams, F. W. Asselbergs, A. K. Al-Ali, F. A. Al-Muhanna, A. M. Al-Rubaish, N. Y. Y. Al-Windy, M. Alkhalil, Y. A. Almubarak, A. N. Al Nafie, M. Al Shahrani, A. M. Al Shehri, C. Anning, R. L. Anthonio, E. A. Badings, C. Ball, E. A. Van Beek, J. M. Ten Berg, M. Von Bergwelt-Baildon, M. Bianco, O. Blagova, H. Bleijendaal, W. L. Bor, S. Borgmann, A. J. M. van Boxem, F. S. van den Brink, C. Bucciarelli-Ducci, B. C. T. Van Bussel, R. Byrom-Goulthorp, G. Captur, M. Caputo, N. Charlotte, J. vom Dahl, P. Dark, J. De Sutter, C. Degenhardt, C. E. Delsing, S. Dolff, H. G. R. Dorman, J. T. Drost, L. Eberwein, M. E. Emans, A. G. Er, J. B. Ferreira, M. J. Forner, A. Friedrichs, L. Gabriel, B. E. Groenemeijer, A. L. Groenendijk, B. Gruener, W. Guggemos, H. E. Haerkens-Arends, F. Hanses, B. Hedayat, D. Heigener, D. J. van der Heijden, E. Hellou, K. Hellwig, M. T. H. M. Henkens, R. S. Hermanides, W. R. M. Hermans, M. W. J. van Hessen, S. R. B. Heymans, A. D. Hilt, I. C. C. van der Horst, M. Hower, S. H. van Ierssel, N. Isberner, B. Jensen, M. T. Kearney, J. T. Kielstein, B. L. J. H. Kietselaer, M. Kochanek, M. Z. H. Kolk, A. M. H. Koning, P. Y. Kopylov, A. F. M. Kuijper, E. R. P. J. M. Kwakkel-van, J. Lanznaster, M. M. J. M. van der Linden, A. C. J. van der Lingen, G. C. M. Linssen, D. Lomas, M. Maarse, F. J. H. Magdelijns, M. Magro, P. Markart, F. M. A. C. Martens, S. G. Mazzilli, G. P. McCann, P. van der Meer, M. F. L. Meijs, U. Merle, P. Messiaen, M. Milovanovic, P. S. Monraats, L. Montagna, A. Moriarty, A. J. Moss, A. Mosterd, S. Nadalin, J. Nattermann, M. Neufang, P. R. Nierop, J. A. Offerhaus, C. E. E. Van Ofwegen-Hanekamp, E. Parker, A. M. Persoon, C. Piepel, Y. M. Pinto, H. Poorhosseini, S. Prasad, A. G. Raafs, C. Raichle, D. Rauschning, J. Redon, A. C. Reidinga, M. I. A. Ribeiro, C. Riedel, S. Rieg, D. P. Ripley, C. Rommele, K. Rothfuss, J. Ruddel, M. M. Ruthrich, R. Salah, E. Saneei, M. Saxena, D. A. A. M. Schellings, N. T. B. Scholte, J. Schubert, J. Seelig, A. Shafiee, A. C. Shore, C. Spinner, S. Stieglitz, R. Strauss, N. H. Sturkenboom, E. Tessitore, R. J. Thomson, P. J. R. Timmermans, R. A. Tio, F. V. Y. Tjong, L. Tometten, J. Trauth, E. M. Van Craenenbroeck, H. P. A. A. van Veen, C. A. den Uil, M. J. G. T. Vehreschild, L. Veldhuis, T. Veneman, D. O. Verschure, I Voigt, L. Walter, D. J. vande Watering, J. K. de Vries, R. M. A. vande Wal, I. C. D. Westendorp, P. H. M. Westendorp, T. Westhoff, C. Weytjens, E. Wierda, K. Wille, K. de With, M. Worm, P. Woudstra, K. W. Wu, R. Zaal, A. G. Zaman, P. M. van der Zee, L. E. Zijlstra, T. E. Alling, R. Ahmed, E. C. E. Bayraktar-Verver, K. van Aken, Bermudez F. J. Jimenes, C. A. Biole, P. Den Boer-Penning, M. Bontje, M. Bos, L. Bosch, M. Broekman, F. J. F. Broeyer, E. A. W. de Bruijn, S. Bruinsma, N. M. Cardoso, B. Cosyns, van Da D. H. Len, E. Dekimpe, J. Domange, J. L. van Doorn, P. van DOorn, F. Dormal, I. M. J. Drost, A. Dunnink, J. W. M. van Eck, K. Elshinawy, R. M. M. Gevers, D. G. Gognieva, M. van der Graaf, S. Grangeon, A. Guclu, A. Habib, N. A. Haenen, K. Hamilton, S. Handgraaf, H. Heidbuchel, M. Hendriks-van Woerden, B. M. Hessels-Linnemeijer, K. Hosseini, J. Huisman, T. C. Jacobs, S. E. Jansen, A. Janssen, K. Jourdan, G. L. ten Kate, M. J. van Kempen, C. M. Kievit, P. Kleikers, N. Knufman, S. E. van der Kooi, B. A. S. Koole, M. A. C. Koole, K. K. Kui, L. Kuipers-Elferink, I Lemoine, E. Lensink, V van Marrewijk, S. H. van Ierssel, E. J. Meijer, A. J. Melein, D. F. Mesitskaya, C. P. M. van Nes, F. M. A. Paris, M. G. Perrelli, A. Pieterse-Rots, R. Pisters, B. C. Polkerman, A. van Poppel, S. Reinders, M. J. Reitsma, A. H. Ruiter, J. L. Selder, A. van der Sluis, A. I. C. Sousa, M. Tajdini, Tercedor L. Sanchez, C. M. Van de Heyning, H. Vial, E. Vlieghe, H. E. Vonkeman, P. Vreugdenhil, T. A. C. de Vries, A. M. Willems, A. M. Wils, S. K. Zoet-Nugteren

Summary: Patients with heart disease have a higher mortality rate when hospitalized with COVID-19, but there is considerable heterogeneity in the association between different heart disease subtypes and in-hospital mortality. Patients with heart failure are at greatest risk of death during hospitalization with COVID-19.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Correction Infectious Diseases

All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort (vol 8, pg 1, 2021)

Maximilian J. Schons, Amke Caliebe, Christoph D. Spinner, Annika Y. Classen, Lisa Pilgram, Maria M. Ruethrich, Jan Rupp, Susana M. Nunes de Miranda, Christoph Roemmele, Janne Vehreschild, Bjoern-Erik Jensen, Maria Vehreschild, Christian Degenhardt, Stefan Borgmann, Martin Hower, Frank Hanses, Martina Haselberger, Anette K. Friedrichs

INFECTION (2022)

Add to Collection

Article Infectious Diseases

All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort

Maximilian J. Schons, Amke Caliebe, Christoph D. Spinner, Annika Y. Classen, Lisa Pilgram, Maria M. Ruethrich, Jan Rupp, Susana Nunes de Miranda, Christoph Rommele, Janne Vehreschild, Bjoern-Erik Jensen, Maria Vehreschild, Christian Degenhardt, Stefan Borgmann, Martin Hower, Frank Hanses, Martina Haselberger, Anette K. Friedrichs

Summary: The use of antibiotics in COVID-19 patients did not show any positive effects on overall mortality or disease progression, additional studies are needed to further understand this issue and improve rational antibiotic use for COVID-19 patients.

INFECTION (2022)

Add to Collection

Article Infectious Diseases

Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy

Lisa K. Gerecke, Julius J. Schmidt, Carsten Hafer, Gabriele Eden, Stefanie M. Bode-Boeger, Jens Martens-Lobenhoffer, Tobias Welte, Jan T. Kielstein

Summary: This study evaluated the pharmacokinetics of fosfomycin in patients undergoing prolonged intermittent renal replacement therapy. The results showed that patients require a dose of 5g every 8 hours to achieve adequate plasma levels, but drug accumulation may occur depending on dialysis frequency and intensity.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Transplantation

Interim analysis of the COSA (COVID-19 patients treated with the Seraph(R) 100 Microbind(R) Affinity filter) registry

Julius J. Schmidt, Dan Nicolae Borchina, Mariet van't Klooster, Khalida Bulhan-Soki, Reuben Okioma, Larissa Herbst, Diego Sandoval Rodriguez, Vedran Premuzic, Stefan Buettner, Birgit Bader, Wojciech Serednicki, Ewa Zasada, Michael Schmitz, Ralf A. Quabach, Maria Hrincheva, Thomas Fuehner, Jan T. Kielstein

Summary: This study evaluated the safety and efficacy of Seraph(R) 100 treatment for COVID-19 patients. The results showed a 30-day mortality rate of 46.2% and a median treatment time of 5 hours. Adverse events occurred in 8.8% of the treatments. Delayed treatment and bacterial superinfection were associated with higher mortality rates.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)

Add to Collection

Article Multidisciplinary Sciences

Evaluation of the ideal length of the Seldinger needle for internal jugular vein catheter placement

Clara M. Wenzel, Torsten M. Meyer, Dietrich Stoevesandt, Heike Kielstein, Jan T. Kielstein

Summary: Placement of central venous catheters (CVC) into the internal jugular vein is a routine intervention, but carries a significant risk of complications. This study found that the average Seldinger needle length currently used is too long, increasing the risk of injury. Shorter needles are sufficient to reach the internal jugular vein and minimize the risk of severe injury to nearby structures.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Infectious Diseases

SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality)

Lisa Pilgram, Lukas Eberwein, Bjoern-Erik O. Jensen, Carolin E. M. Jakob, Felix C. Koehler, Martin Hower, Jan T. Kielstein, Melanie Stecher, Bernd Hohenstein, Fabian Prasser, Timm Westhoff, Susana M. Nunes de Miranda, Maria J. G. T. Vehreschild, Julia Lanznaster, Sebastian Dolff

Summary: This multicentre cohort study aimed to evaluate the situation of CKD5D patients during the COVID-19 pandemic and investigate the association between dialysis dependency and mortality. The results showed that dialysis dependency was not related to mortality, but the mortality rate of CKD patients was high.

INFECTION (2023)

Add to Collection

Review Critical Care Medicine

Plasma exchange in the intensive care unit: a narrative review

Philippe R. Bauer, Marlies Ostermann, Lene Russell, Chiara Robba, Sascha David, Bruno L. Ferreyro, Joan Cid, Pedro Castro, Nicole P. Juffermans, Luca Montini, Tasneem Pirani, Andry Van De Louw, Nathan Nielsen, Julia Wendon, Anne C. Brignier, Miet Schetz, Jan T. Kielstein, Jeffrey L. Winters, Elie Azoulay

Summary: This narrative review discusses the relevant issues of therapeutic plasma exchange (TPE) in critically ill patients. Uncertainty remains regarding the optimal indications, device types, replacement fluids, and other aspects of TPE. TPE is potentially life-saving but carries risks and requires close monitoring by experienced teams.

INTENSIVE CARE MEDICINE (2022)

Add to Collection

Letter Pharmacology & Pharmacy

Letter to the editor concerning the case report Successful treatment of severe quetiapine intoxication with CytoSorb hemoadsorption

Jan T. Kielstein, Julius J. Schmidt, Marc Ghannoum

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

Add to Collection

Letter Critical Care Medicine

Cytokine Adsorption: It's About the Precise Tactics Reply

Alexander Zarbock, Jan T. Kielstein

CRITICAL CARE MEDICINE (2022)

Add to Collection

Article Immunology

Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice

Sophie Dennhardt, Wiebke Pirschel, Bianka Wissuwa, Diana Imhof, Christoph Daniel, Jan T. Kielstein, Isabel Hennig-Pauka, Kerstin Amann, Florian Gunzer, Sina M. Coldewey

Summary: Hemolytic-uremic syndrome (HUS) is a systemic complication of infections with Shiga toxin-producing Escherichia coli, characterized by microangiopathic hemolytic anemia and acute kidney injury. This study found that endogenous erythropoietin (EPO) levels were elevated in HUS patients and animal models. Administration of EPO and its analog pHBSP improved survival and attenuated renal oxidative stress in mice with HUS. Therefore, repurposing EPO for the treatment of hemolytic anemia in HUS should be further investigated in clinical trials.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Urology & Nephrology

More Drug Monitoring and Less CT Scans of the Brain: Gabapentin Overdose in Two Peritoneal Dialysis Patients

Kijanosh Lehmann, Sara Diab, Torsten M. Meyer, Jan T. Kielstein, Gabriele Eden

Summary: With declining renal function, dosing of drugs becomes more challenging, especially for patients undergoing kidney replacement therapy. The use of medications like gabapentin in dialysis patients requires tight control and monitoring to prevent unintended overdose. In patients with renal impairment, excretion of gabapentin is reduced and plasma concentrations increase, highlighting the importance of careful dosing and monitoring in this population.

CASE REPORTS IN NEPHROLOGY AND DIALYSIS (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.